Cancer Immunotherapy News and Research

RSS

Good-guy bacteria may help individuals respond well to cancer immunotherapy

Individuals with certain types of bacteria in their gut may be more likely to respond well to cancer immunotherapy, researchers at the Harold C. Simmons Comprehensive Cancer Center found in a study of patients with metastatic melanoma.

5 Oct 2017

Huddersfield cancer scientists aim to develop new treatments for young people

CANCER researchers at the University of Huddersfield aim to develop new treatments specifically for young people and they will be aided in their quest by financial support from a locally-based charity.

27 Sep 2017

Cancer-fighting cells destroy tumors more effectively after being starved for oxygen

Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions.

18 Sep 2017

Study findings may have critical implications to boost efficacy of T cell-based therapies

T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy.

11 Sep 2017

Generic drug used to increase blood flow may improve effectiveness of cancer immunotherapy

Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.

7 Sep 2017

$Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL$

Novartis gets FDA approval for novel immunocellular therapy to treat relapsed or refractory B-cell ALL

Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

30 Aug 2017

Researchers develop new approach to efficiently produce versatile antibody therapies

A group of researchers has developed an approach to efficiently produce antibodies that can bind to two different target molecules simultaneously, a long-desired innovation in the field of cancer immunotherapy.

29 Aug 2017

Immune booster could improve effectiveness of vaccines and cancer immunotherapy

Vaccines and cancer immunotherapies do essentially the same thing: They boost a person's immune system, better enabling it to fight an offender, be it microbe or malignancy.

29 Aug 2017

NIH grant for CWRU professors could enable new directions for cancer immunotherapies

Nicole Steinmetz, PhD, Associate Professor of Biomedical Engineering, Radiology, member of the Case Comprehensive Cancer Center and the Center for RNA Science and Therapeutics in the Division of General Medical Sciences at Case Western Reserve University School of Medicine and the holder of the George J. Picha Designated Professor in Biomaterials, has received a major grant from the National Institutes of Health to help understand how a virus-like particle from plants stimulates potent anti-tumor responses.

26 Aug 2017

Combination treatment effectively vaccinates mice against cancer

By combining an FDA-approved cancer immunotherapy with an emerging tumor-roasting nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice.

18 Aug 2017

Sanford Health launches solid tumor oncolytic virus clinical trial

Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors.

17 Aug 2017

Fred Hutch aims to prevent and find cures for cancers caused by infectious agents

Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents.

10 Aug 2017

Study: Response to combination immunotherapy in melanoma depends on proportion of immune cells

Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco researchers joined by physicians from UCSF Health.

20 Jul 2017

Engineered macrophages invade and engulf tumor cells in mouse models

One reason cancer is so difficult to treat is that it avoids detection by the body. Agents of the immune system are constantly checking the surfaces of cells for chemical signals that say they belong, but cancer cells express the same chemical signals as healthy ones.

19 Jul 2017

CNIC research holds potential to improve current cancer immunotherapy strategies

Researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III have investigated how different subtypes of essential immune-response cells called CD8+ T lymphocytes cooperate to mount a stronger anti-tumor response.

17 Jul 2017

CWRU researcher receives major NIH grants to develop microscopic drug-delivery systems

Nicole F. Steinmetz, PhD, George J. Picha Professor in Biomaterials, member of the Case Comprehensive Cancer Center, and Director of the Center for Bio-Nanotechnology at Case Western Reserve School of Medicine, has received two major grants from the National Institutes of Health to develop microscopic drug-delivery systems for patients living with breast cancer, and patients at risk for serious blood clots.

29 Jun 2017

Scientists develop new algorithm to decipher how immune system recognizes and binds antigens

Scientists from St. Jude Children's Research Hospital and Fred Hutchinson Cancer Research Center have developed an algorithm that functions like a Rosetta Stone to help decipher how the immune system recognizes and binds antigens.

22 Jun 2017

'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs

In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab.

9 Jun 2017

Greater gut bacteria diversity linked to longer progression-free survival in metastatic melanoma patients

The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center report at the 2017 annual meeting of the American Society of Clinical Oncology.

6 Jun 2017

As government-funded cancer research sags, scientists fear U.S. is ‘losing its edge’

Less and less of the research presented at a prominent cancer conference is supported by the National Institutes of Health, a development that some of the country's top scientists see as a worrisome trend.

2 Jun 2017